Tumor Stroma Targeting via FAP

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL049
Release Date: June of 2019

Tumor Stroma Targeting via FAP – Target Pipeline List 06/2019

Targets: Fibroblast activation protein; FAP

This Target Pipeline List provides an overview of FAP-targeted antibodies, fusion proteins and oncolytic viruses in development for treatment of stroma rich tumors.

Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.

Targeting of FAP is well suited for tumor stroma delivery of effector moieties such as cytokines, co-stimulatory agonists, redirected cytotoxic T-cells, and oncolytic viruses. Accordingly, antibody-based and multimeric fusion proteins as well as engineered oncolytic viruses with transgenes are in development for treatment of stroma rich tumorws.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01